Meeting
2022 ASCO Quality Care Symposium
Real-world variability in use of bone-modifying drugs for multiple myeloma by payer type.
Authors
SOPHIA Monica Monica Soni
915 W. Imperial Highway, Brea, CA
SOPHIA Monica Monica Soni, Andrew Allan Hertler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Access to Treatment
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 129)
DOI
10.1200/JCO.2022.40.28_suppl.129
Abstract #
129
Poster Bd #
D28
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Treatment initiation with bone-targeting agents among patients with bone metastasis secondary to solid tumors or patients with multiple myeloma.
First Author: Oth Tran
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Treatment, logistical, and cost burden of prior authorization in community practice.
First Author: Ajaz Bulbul
Poster
2023 ASCO Quality Care Symposium
Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2023 ASCO Quality Care Symposium
Frequency of anti-resorptive therapy prescription and skeletal disease screening in patients diagnosed with multiple myeloma.
First Author: Amman Bhasin